Efficacy and safety of human mesenchymal stromal cells in healing of critical-size bone defects in immunodeficient rats
Language English Country Czech Republic Media print-electronic
Document type Journal Article
PubMed
27782744
DOI
10.33549/physiolres.933376
PII: 933376
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Femur diagnostic imaging physiology MeSH
- Wound Healing physiology MeSH
- Rats MeSH
- Middle Aged MeSH
- Humans MeSH
- Mesenchymal Stem Cells physiology MeSH
- Random Allocation MeSH
- Osteogenesis physiology MeSH
- Tomography, X-Ray Computed methods MeSH
- Rats, Nude MeSH
- Aged MeSH
- Immunologic Deficiency Syndromes diagnostic imaging immunology therapy MeSH
- Mesenchymal Stem Cell Transplantation methods MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Adult MeSH
- Rats MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
To evaluate the preclinical efficacy and safety of human mesenchymal stem cells (hMSC) rapidly expanded in growth medium for clinical use with human serum and recombinant growth factors, we conducted a controlled, randomized trial of plasma clots with hMSC vs. plasma clots only in critical segmental femoral defects in rnu/rnu immunodeficient rats. X-ray, microCT and histomorphometrical evaluation were performed at 8 and 16 weeks. MSC were obtained from healthy volunteers and patients with lymphoid malignancy. Human MSC survived in the defect for the entire duration of the trial. MSC from healthy volunteers, in contrast to hMSC from cancer patients, significantly improved bone healing at 8, but not 16 weeks. However, at 16 weeks, hMSC significantly improved vasculogenesis in residual defect. We conclude that hMSC from healthy donors significantly contributed to the healing of bone defects at 8 weeks and to the vascularisation of residual connective tissue for up to 16 weeks. We found the administration of hMSC to be safe, as no adverse reaction to human cells at the site of implantation and no evidence of migration of hMSC to distant organs was detected.
References provided by Crossref.org
Application of modified mesenchymal stem cells transplantation in the treatment of liver injury